文献速递脑血管病

比较平扫CT、多时相CT血管成像与CT灌注评估急性卒中梗死生长速率

Comparison of Noncontrast Computed Tomography, Multiphase Computed Tomography Angiography, and Computed Tomography Perfusion to Assess Infarct Growth Rate in Acute Stroke.
PubMed 文献 · Stroke · 2025-02-10

该研究为ESCAPE-NA1试验的二次分析,纳入1105例接受取栓的大血管闭塞性急性缺血性卒中患者,分别用平扫CT的ASPECTS衰减、多时相CTA的侧支状态和CT灌注的灌注不足强度比来估计梗死生长速率。结果显示,仅基于CT灌注标准定义的进展表型与90天改良Rankin量表评分相关,而基于平扫CT和mCTA标准定义的表型未见显著关联。

要点

  • CT灌注的灌注不足强度比定义的进展表型与90天功能结局相关(校正共同OR 1.69)。
  • 平扫CT的ASPECTS衰减和mCTA侧支状态定义的进展表型与90天mRS无显著关联。
  • 仅部分患者有CT灌注数据(415/1105,37.6%),结果需谨慎解读。

核心结论

  • 基于CT灌注标准(灌注不足强度比方法)的卒中进展表型与临床结局相关,而基于平扫CT(ASPECTS衰减)和mCTA(侧支状态)标准的进展表型则无显著关联。

研究设计与样本

  • 国际ESCAPE-NA1试验(评估Nerinetide治疗急性缺血性卒中疗效与安全性)的二次分析,纳入接受取栓的大血管闭塞患者1105例。
  • 梗死生长速率分别用平扫CT的ASPECTS衰减(每小时)、多时相CTA的侧支状态和CT灌注的灌注不足强度比来估计。
  • 根据中位ASPECTS衰减、mCTA侧支良好与中等/差、以及中位灌注不足强度比,将患者二分为中间进展者和缓慢进展者。
  • 采用校正逻辑回归分析评估各神经影像模态定义的进展表型与90天改良Rankin量表评分的关联。

主要发现

  • 1105例患者中,619例(56.0%)用平扫CT评估进展表型,1084例(98.1%)用mCTA,415例(37.6%)用CT灌注。
  • 中位ASPECTS衰减为每小时1.05(四分位距0.05-1.85),188/1084例(17%)患者mCTA侧支状态良好,中位灌注不足强度比为0.44(四分位距0.28-0.59)。
  • 仅在CT灌注分层中,中间进展者相比缓慢进展者功能结局更差:改良Rankin量表序数移位分析的校正共同OR为1.69(95% CI 1.14-2.49)。
  • 使用平扫CT和mCTA方法时,进展表型与90天改良Rankin量表评分未见显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infarct growth rate is remarkably heterogeneous in acute ischemic stroke, reflecting diverse clinical-physiological phenotypes. We compared different methods of estimating infarct growth rate in patients with acute ischemic stroke undergoing thrombectomy using multimodal computed tomography (CT) stroke imaging. METHODS: Secondary analysis of the international ESCAPE-NA1 trial (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke) which evaluated the effect of nerinetide in patients with large vessel occlusion undergoing thrombectomy. Infarct growth rate was estimated leveraging each component of multimodal stroke CT imaging: (1) 10 minus baseline Alberta Stroke Program Early CT Score (ASPECTS) divided by hours elapsed from symptom onset on noncontrast CT (ASPECTS decay per hour); (2) collateral status on multiphase CT angiography (mCTA), and (3) hypoperfusion intensity ratio on CT perfusion. Patients were dichotomized into intermediate and slow progressors (since fast progressors were likely to be excluded from ESCAPE-NA1 based on trial enrollment criteria) according to median ASPECTS decay, presence of good versus moderate/poor mCTA collaterals, and median hypoperfusion intensity ratio, respectively. Associations between progressor phenotypes and 90-day modified Rankin Scale score were assessed across neuroimaging modalities using adjusted logistic regression analyses. RESULTS: Among 1105 patients enrolled in ESCAPE-NA1 between 2017 and 2019, 619 (56.0%) were assessed for progressor phenotypes using noncontrast CT, 1084 (98.1%) with mCTA, and 415 (37.6%) with CT perfusion. Median ASPECTS decay per hour was 1.05 (interquartile range, 0.05-1.85), 188/1084 (17%) patients had good collateral status on mCTA, and the median hypoperfusion intensity ratio was 0.44 (interquartile range, 0.28-0.59). Intermediate progressors showed worse functional outcomes compared with slow progressors only in CT perfusion strata: adjusted common odds ratio for modified Rankin Scale ordinal shift analysis of 1.69 (95% CI, 1.14-2.49). No significant association between progressor phenotypes and 90-day modified Rankin Scale was seen when the noncontrast CT and the mCTA approaches were used. CONCLUSIONS: Stroke progressor phenotypes based on CT perfusion criteria (using the hypoperfusion intensity ratio approach) were associated with clinical outcomes, while stroke progressor phenotypes based on noncontrast CT (ASPECTS decay) and mCTA (collateral status) criteria were not.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Pensato U, Bosshart SL, Stebner A, et al. Comparison of Noncontrast Computed Tomography, Multiphase Computed Tomography Angiography, and Computed Tomography Perfusion to Assess Infarct Growth Rate in Acute Stroke. Stroke. 2025. PMID: 39925291. doi:10.1161/STROKEAHA.124.047680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。